Details for New Drug Application (NDA): 010349
✉ Email this page to a colleague
NDA 010349 describes SPARINE, which is a drug marketed by Wyeth Ayerst and Hikma and is included in three NDAs. Additional details are available on the SPARINE profile page.
The generic ingredient in SPARINE is promazine hydrochloride. There are thirty-seven drug master file entries for this compound. Additional details are available on the promazine hydrochloride profile page.
The generic ingredient in SPARINE is promazine hydrochloride. There are thirty-seven drug master file entries for this compound. Additional details are available on the promazine hydrochloride profile page.
Summary for 010349
| Tradename: | SPARINE |
| Applicant: | Hikma |
| Ingredient: | promazine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 010349
Profile for product number 006
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 50MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 008
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 25MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
